Skip to content

Depreciation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×
Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's depreciation?
Wave Life Sciences (WVE) reported depreciation of $841K in Q1 2026.
How has Wave Life Sciences's depreciation changed year-over-year?
Wave Life Sciences's depreciation decreased by 3.9% year-over-year, from $875K to $841K.
What is the long-term trend for Wave Life Sciences's depreciation?
Over 4 years (2021 to 2025), Wave Life Sciences's depreciation has grown at a -17.7% compound annual growth rate (CAGR), from $7.48M to $3.44M.